Roivant Sciences

Biotech · Private

Biotech subsidiary company creation platform developing therapeutics from undervalued drug assets

roivant.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3070Arrowhead Pharmaceuticals——
3071XTEM PHARMACEUTICALS, INC.——
3072SENEB BIOSCIENCES, INC.——
3073Roivant Sciences——
3074ADVANCED GENETIC SYSTEMS, INC.——
3075IQ PROTEOMICS, LLC——
3076MAGGIE'S PEARL, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Diaryl And Arylheteroaryl Urea Derivatives As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Prophylaxis And Treatment Of Rem Sleep Behavior Disorderapplication
  • Diaryl And Arylheteroaryl Urea Derivatives As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Prophylaxis And Treatment Of Rem Sleep Behavior Disorderapplication
  • Diaryl And Arylheteroaryl Urea Derivatives As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Prophylaxis And Treatment Of Rem Sleep Behavior Disorderapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.